Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. - Wikidata - awgldk - TriplyDB

Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.

Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.

http://www.wikidata.org/entity/Q33781150

about

Natural Killer Cells for Therapy of Leukemia Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Cord Blood as a Source of Natural Killer Cells Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer Alloreactive Natural Killer Cells for the Treatment of Acute Myeloid Leukemia: From Stem Cell Transplantation to Adoptive Immunotherapy Immune Modulation in Hematologic Malignancies T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect The role of regulatory T cells in cancer immunology Functional Reconstitution of Natural Killer Cells in Allogeneic Hematopoietic Stem Cell Transplantation Manufacturing Natural Killer Cells as Medicinal Products Improving natural killer cell cancer immunotherapy Natural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation.Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.Preliminary evaluation of a highly automated instrument for the selection of CD34+ cells from mobilized peripheral blood stem cell concentrates Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists.Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation.Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications.Haematological malignancies: at the forefront of immunotherapeutic innovation.Natural killer cell therapy in children with relapsed leukemia.Challenges and opportunities of allogeneic donor-derived CAR T cells Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity Elevated lymphocyte count at time of acute myeloid leukemia diagnosis is associated with shorter remission.Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.Leukemia-associated activating mutation of Flt3 expands dendritic cells and alters T cell responses.Repression of GSK3 restores NK cell cytotoxicity in AML patients.UV-inactivated HSV-1 potently activates NK cell killing of leukemic cells.Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.New approaches for the immunotherapy of acute myeloid leukemia.The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer.Natural Killer Cell Immunotherapy: From Bench to Bedside Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer.NK cell-based cancer immunotherapy: from basic biology to clinical application.Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot.Natural Killer Cell-Based Cancer Immunotherapies: From Immune Evasion to Promising Targeted Cellular Therapies Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy.

P2860

Q26745906-5CF31B7D-05DC-4B1D-832F-5FF9D5D0FC31 Q26770391-A2372246-7D33-442A-806C-47DFE51DAE11 Q26771337-56983A7D-2806-49D9-AB95-D5D1F3C9C095 Q26773135-FE7C6B16-4F78-43A4-9A67-2BD4D044F0C4 Q26774678-1D866B89-17D4-4E92-8D35-CD0E05CA5EBF Q26777209-0530A51F-D5AB-41CD-B4CE-1784F1752297 Q26796307-6D13DD1E-F158-484F-9178-7605CE7B702A Q26826830-E11AD86D-7CEB-4AB3-8075-469B960C6AF8 Q27006663-2E49613A-72A2-496D-A937-1CAC2D816E7A Q28069682-8FDD77D2-843C-42D4-BE73-6F129C05B1BD Q28069992-FBA60756-5B37-491A-B02D-28EF964BFD3B Q28087719-541E23BB-CEC5-43CC-B69B-AF3E801DAF7A Q33600093-D3A6763C-E1FD-4C52-8AA0-7B07D09A805C Q33703046-ECAB6CEE-FFD8-4B66-93AE-D91E60204FD0 Q33922539-97145600-3B83-4E7A-9C76-AAB927CC6F86 Q34180695-71B5D380-9C71-477B-A586-63ADBD7E235E Q34553267-D697435B-D866-459E-897C-9A99C044EE51 Q35029441-5FD0DA3F-2948-44E1-AC59-253152AF4D84 Q35600095-F9089958-AA46-455F-9445-A8B90BF98842 Q35711209-871285B2-EA69-4D56-B756-362B0DBFED2A Q35880618-50B46BF9-D422-46AD-A545-2E67C266AD70 Q36251948-4C2C2CB3-55A3-463B-A7A6-89F6ED4A750F Q36257036-EF048094-9F53-4432-A28A-5C804E8FABD1 Q36435156-763717B5-B5CE-4689-9CEA-742594D430E6 Q36467544-6293762C-A4BB-4B66-9EFC-08CCFA76377C Q36712059-6C05B5AE-06DC-40A5-A9C2-AD194A68D008 Q36745048-E04A7B12-AF3A-498A-9E0D-CA0DD05AA198 Q36768725-13414453-7A5C-40C1-880C-59BC2AC8C558 Q36966726-B58F58B1-C6C2-4FD4-9FCB-04AC7F2783FA Q37058110-14A63E55-B930-468A-8931-211982226A2A Q37517482-ED51C2DA-17FE-4D6F-BB03-768A4673FF67 Q37624593-BBDF591D-D9F6-4C7E-87A7-35E0FF3A87C4 Q38482206-5F24D946-67F7-4654-BB88-F0BC40A07B4F Q38513534-B5C58758-5CB9-4A89-8CEB-3EC542E478CE Q38531958-7C3BE0A4-7A2B-4883-8F7B-E53C6972F32F Q38599353-A8EBFE6A-6F2B-418B-B291-48928E9B01BA Q38640489-8AB21323-BB4A-464B-987D-E350EAD8B291 Q38643300-D508C957-8097-4DB3-807B-86536249599D Q38651290-0751FA43-7DFC-43F0-91B5-7CDE2F53C1DD Q38666579-2000AD7D-7BC1-4475-A5AF-818A08BD4D6F

P2860

Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.

http://www.wikidata.org/entity/Q33781150

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Clearance of acute myeloid leu ...... phtheria toxin fusion protein.

@ast

Clearance of acute myeloid leu ...... phtheria toxin fusion protein.

@en

type

label

Clearance of acute myeloid leu ...... phtheria toxin fusion protein.

@ast

Clearance of acute myeloid leu ...... phtheria toxin fusion protein.

@en

prefLabel

Clearance of acute myeloid leu ...... phtheria toxin fusion protein.

@ast

Clearance of acute myeloid leu ...... phtheria toxin fusion protein.

@en

P1433

Q33781150-FC3C7C0B-C809-4D5E-9277-92AE5BC7E13C

P1476

Q33781150-71BD7CC9-1BC0-432A-A253-FD91032BA6D6

P2093

Q33781150-066C806E-AA1C-461C-BAB5-C7EF69EC9422

Q33781150-09D3EFFE-7BEB-4DF3-957D-9DC48DFD92AF

Q33781150-142193D2-61D4-45D6-92F7-D5904135C594

Q33781150-24CB0CD8-7FBE-4C51-AB56-3F0ED6439865

Q33781150-46CD1EC1-F4D6-42AA-8E57-B7199E8741B6

Q33781150-5F9C0EEC-08D6-4D30-AD4B-B8B5C8700CA5

Q33781150-7A5B2A5D-10C8-47F4-BCFE-6527B8F538E7

Q33781150-80C3B8B3-1A1E-4E62-B62D-4291693B911E

Q33781150-8BFA6A1B-02AE-4B06-AB8A-AE933770FD4D

Q33781150-99FD3A33-B715-40C5-BC14-63570FCA8C87

P2860

Q33781150-1431D7E5-287A-4810-ABD1-110805EA1926

Q33781150-14351DA6-1479-42EE-A307-3D4EB7708B18

Q33781150-220432CE-7CCF-4689-9836-E611AD421B80

Q33781150-2555B31F-9887-402D-ADE6-FD3B40F2B171

Q33781150-28EFF971-B510-4CEA-9BBA-D6D515DF1979

Q33781150-2BE1B3E0-505B-409A-A622-E2BC16A1D80E

Q33781150-2F6D6292-FEF5-4A91-8CE7-998D10A8A7B2

Q33781150-3142831E-E486-4C26-A9B6-BB960B2944F4

Q33781150-42F738C0-BE68-4E78-9F08-24432CCB9AAC

Q33781150-489D91CB-73BF-4ED6-B659-AC175B8AEB57

P304

Q33781150-514C0778-5371-4198-AC50-57EC5A721159

P31

Q33781150-58E2AE73-A5FB-4985-A943-DEB3CC9DFEE5

P356

Q33781150-83CC6507-138C-415D-A0CE-CB49F910E249

P407

Q33781150-9E3FCCA3-32F8-4C1B-8BEC-039290D3A53A

P433

Q33781150-6606C67F-441F-48F5-B389-21362923FD41

P478

Q33781150-C25E0CBD-744D-4980-AFC8-1372AB4EA0EF

P50

Q33781150-4DC49AAB-05AC-4AA8-9B54-CBBF4DB3242D

Q33781150-D7D04B64-6A38-4273-9957-B5EA1DFFA5E8

P577

Q33781150-E05256FF-B23F-4949-B86D-3C424AC3BBF0

P5875

Q33781150-F65E976C-E03C-493D-A20D-30D6EEFCD455

P698

Q33781150-ADC3797B-3C0C-42D2-947C-C23226DB2C56

P921

Q33781150-108B032F-21FD-4EBC-B669-DC109612847A

P932

Q33781150-F8CE872C-BE9B-466F-93DE-72E491B5E452

P356

BLOOD-2013-10-532531

P1433

P1476

Clearance of acute myeloid leu ...... phtheria toxin fusion protein.

@en

P2093

Bin Zhang

http://www.w3.org/2001/XMLSchema#string

Daniel J Weisdorf

http://www.w3.org/2001/XMLSchema#string

David H McKenna

http://www.w3.org/2001/XMLSchema#string

Dixie Lewis

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Miller

http://www.w3.org/2001/XMLSchema#string

Julie Curtsinger

http://www.w3.org/2001/XMLSchema#string

Keli Hippen

http://www.w3.org/2001/XMLSchema#string

Michael R Verneris

http://www.w3.org/2001/XMLSchema#string

Philip McGlave

http://www.w3.org/2001/XMLSchema#string

Sarah Cooley

http://www.w3.org/2001/XMLSchema#string

P2860

Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells

Regulation of lymphoid homeostasis by interleukin-15

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

NK cell recognition

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

Allogeneic natural killer cells for refractory lymphoma

Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells.

DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology.

Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2.

P304

3855-3863

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-10-532531

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

Angela Panoskaltsis-Mortari

P577

2014-04-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261521372

http://www.w3.org/2001/XMLSchema#string

P698

24719405

http://www.w3.org/2001/XMLSchema#string

P921

P932

4064329

http://www.w3.org/2001/XMLSchema#string